drugset
drugset / Trial / NCT07193550

A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)

NCT07193550 ↗

Phase 2 Recruiting 70 enrolled M.D. Anderson Cancer Center Exelixis · collab
NaSingle-groupOpen-labelTreatment

Summary

To study the treatment efficacy of zanzalintinib monotherapy in patients with advanced and/or metastatic bone sarcomas.

Timeline

Start
2025-12-05
Primary completion
2029-10-31
Completion
2031-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Zanzalintinib Small molecule 100 mg Oral

Indications

bone sarcoma